This article takes about 4 minutes to read

LABU Basics - 3x Leverage on Biotechnology

LABU (Direxion Daily S&P Biotech Bull 3X Shares) targets 3x the daily return of the S&P Biotechnology Select Industry Index. Launched May 28, 2015 by Direxion. Expense ratio 0.95%. Net assets ~$1.5 billion.

The underlying index uses modified equal-weighting across ~130-150 biotech companies from large to small cap. This equal-weighting characteristic dramatically shapes LABU's risk profile.

Average daily volume is ~20-30 million shares. LABU ranks among the highest-risk leveraged ETFs. Daily swings of +/-30% can occur. Investing requires accepting potential total loss on a small allocation.

The combination of biotech's inherent volatility with 3x leverage creates one of the most extreme risk products available to retail investors.

Biotech Sector Characteristics - A Collection of Binary Risks

Biotech stock prices move dramatically on FDA approval decisions. Approval can send stocks +50-200%; rejection causes -50-80% crashes. This binary risk drives the entire sector's elevated volatility.

Clinical trial results (Phase 1/2/3), FDA Complete Response Letters, and PDUFA dates all trigger massive price moves. These events are difficult to predict, carrying uncertainty beyond fundamental analysis.

M&A activity (large pharma acquiring biotechs) is another major factor. Acquisition premiums typically run 30-100%. The sector's annualized volatility of 30-40% is over double the S&P 500's 15-18%.

At 3x leverage, LABU's effective volatility reaches 90-120% annualized. Theoretical annual decay: -3 × (0.35)² ≈ -36.75%, the highest among all major leveraged ETFs.

Equal-Weighting Means Small-Cap Dominance

LABU's equal-weighted index is a critical but often overlooked feature. In cap-weighted indices, large stocks dominate. In equal-weighting, a $10 billion large-cap and a $500 million small-cap have roughly equal index impact.

Small biotechs are far more volatile than large ones. Companies with only 1-2 pipeline drugs can see +200% or -80% moves on a single trial result. Equal-weighting amplifies these extreme small-cap moves across the entire index.

With 150 constituents, one company's -70% FDA rejection impacts the index by ~-0.47%. Multiple small-caps reporting bad news simultaneously can significantly drag the index down.

LABU is effectively a bet on small-cap biotech aggregates rather than the biotech sector broadly. Large-cap stability (Amgen, Gilead, Regeneron) is diluted by equal-weighting. Do not mistake LABU for large-cap biotech exposure.

Extreme Historical Price Moves

During the 2020 COVID crash, LABU fell over -80% from highs. In February 2021, the meme stock boom lifted LABU +80% in one month. Then from February 2021 to May 2022, LABU declined over -90%.

The 2022 decline was devastating. Rising rates crushed unprofitable growth stocks, and biotech was sold as the poster child of revenue-less growth. Many small biotechs fell -80-90%, and the equal-weighted index was decimated.

From February 2021 high to May 2022 low, LABU fell over -95%. Recovering from -95% requires +1,900%, equivalent to the sector rising ~6.3x from bottom. This takes years.

These numbers demonstrate how dangerous long-term LABU holding can be. The product can effectively go to near-zero.

Decay Rate Comparison with Other 3x ETFs

Comparing annual decay rates: SPXL (S&P 500, σ≈16%): -7.7%. TQQQ (NASDAQ100, σ≈20%): -12%. SOXL (semiconductors, σ≈30%): -27%. LABU (biotech, σ≈35%): -36.75%.

LABU's -36.75% annual decay means the underlying must return +36.75%+ annually just to match a 1x investment. Biotech's historical annual return of ~+8-12% falls far short. This means LABU long-term holding is structurally disadvantaged.

Actual data confirms this: LABU's total return since 2015 inception significantly underperforms XBI (1x biotech). Over 2015-2025, XBI was roughly flat while LABU lost over -70%. Decay completely consumed the underlying's returns.

This proves not all leveraged ETFs outperform their index long-term. TQQQ and SPXL succeeded because their underlying returns exceeded decay. LABU fails this condition.

Guidelines for LABU Investment

First, avoid long-term holding. LABU structurally loses to decay over time. Limit to short-term trend-following strategies.

Second, cap allocation at 2-3% of portfolio. LABU has experienced -95% declines. If 3% goes to near-zero, overall portfolio impact is limited to -3%.

Third, invest only when clear catalysts exist: M&A waves, FDA approval rushes, or policy tailwinds for the sector. Holding passively is equivalent to donating capital to volatility decay.